Sort   by:  
 Page size 
ProteomicsQuantitative phosphoproteomic analysis of acquired drug resistance to pazopanib and dasatinib
Acquired drug resistance and tumour relapse impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapeutic strategies to overcome drug resistance represents a significant un...
ORGANISM(S): Homo sapiens (Human) 
2017-08-30 | PXD005536 | Pride
Resistance Dasatinib Pazopanib A204 Phosphoproteomics 
TranscriptomicsmicroRNAs as predictive biomarkers of response to sunitinib or pazopanib in patients with metastatic renal cell carcinoma
The aim of the experiment was to discover differentially expressed miRNAs correlating with prolonged response to targeted therapy in patients with metastatic renal cell carcinoma treated with sunitinib or pazopanib
ORGANISM(S): Homo sapiens 
2018-02-08 | E-MTAB-6296 | biostudies-arrayexpress
GenomicsNeoadjuvant Pazopanib and Molecular Analysis of Tissue Response in Renal Cell Carcinoma
Neoadjuvant Pazopanib and Molecular Analysis of Tissue Response in Renal Cell Carcinoma
PRJNA641945 | ENA
GenomicsNeoadjuvant Pazopanib and Molecular Analysis of Tissue Response in Renal Cell Carcinoma
Neoadjuvant Pazopanib and Molecular Analysis of Tissue Response in Renal Cell Carcinoma
PRJNA641944 | ENA
GenomicsA multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans
A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans
PRJNA633581 | ENA
GenomicsA lncRNA HAR1B has a potential as a predictive marker for pazopanib therapy in patients with sarcoma
A lncRNA HAR1B has a potential as a predictive marker for pazopanib therapy in patients with sarcoma
PRJNA657571 | ENA
GenomicsA lncRNA HAR1B has a potential as a predictive marker for pazopanib therapy in patients with sarcoma
Bone and soft tissue sarcomas are rare and highly heterogeneous mesenchymal malignancies. Their rarity makes it difficult to acquire clinical data of patients with specific histological subtypes of sarcoma from large clinical trials. The diagnoses and treatment of sarcomas need to be further develop...
ORGANISM(S): Homo sapiens 
2021-04-28 | GSE156344 | GEO
TranscriptomicsExpression data for iPSC-derived hepatocyte-like cells (HLCs) treated with 100 µM pazopanib for 24 hours
Pazopanib is a drug with idiosyncratic hepatotoxicity risk. Analysis of gene expression changes after exposing hepatocytes can indicate effects on specific biological pathways and potential mechanisms of hepatotoxicity. HLCs derived from patient-specific iPSCs were treated with pazopanib to identify...
ORGANISM(S): Homo sapiens 
2016-09-30 | GSE75888 | GEO
TranscriptomicsA multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans
Dermatofibrosarcoma protuberans (DFSP) is a soft-tissue sarcoma characterized by a high risk of local infiltration. The identification of the COL1A1-PDGFB t(17;22) translocation activating the PDGF pathway led to the use of imatinib in unresectable DFSP, with a response rate of 36-80%. Pazopanib is ...
ORGANISM(S): Homo sapiens 
2020-05-19 | GSE150787 | GEO
UnknownPazopanib in advanced soft tissue sarcomas.
Not available
S-EPMC6522548 | biostudies-literature
Sort   by:  
 Page size